Search

Your search keyword '"Santaballa A"' showing total 1,170 results
Start Over Author "Santaballa A"
1,170 results on '"Santaballa A"'

1. Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors: the Greko II study (GETHI2013-01)

Author

Garcia-Donas, Jesus, Garrigos, Laia, Lainez, Nuria, Santaballa, Ana, Redondo, Andres, Cueva, Juan Fernando, Rubio, Mª Jesus, Prieto, Mario, Lopez-Guerrero, Jose Antonio, Garcia-Casado, Zaida, Barquin, Aranzanzu, Grande, Enrique, Alia, Eva Guerra, Sevillano, Elena, Bover, Isabel, Grazioso, Tatiana P, Sanchez-Escribano, Ramón, Hurtado, Alicia, Navarro, Paloma, and Rodriguez-Moreno, Juan Francisco

Published
2024
Full Text
View/download PDF

2. Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study

Author

Rodríguez-Lescure, Álvaro, Gallego, Javier, Garcia-Alfonso, Pilar, Massuti, Bartomeu, Márquez, Raúl, Calvo, Lourdes, Sánchez-Rovira, Pedro, Antón, Antonio, Chacón, José Ignacio, Ciruelos, Eva, Ponce, Jose Juan, Santaballa, Ana, Valladares-Ayerbes, Manuel, Dueñas, María Rosario, Alonso, Vicente, Aparicio, Jorge, Encinas, Sara, Robles, Luis, Escudero, María José, Caballero, Rosalía, Bezares, Susana, and de la Haba-Rodriguez, Juan

Published
2024
Full Text
View/download PDF

3. Looking for Daisies: The Hidden Attraction and Arrival Infrastructures of Welcoming Spaces in Rural Spain

Author

Laura Oso and Leticia Santaballa

Subjects
arrival infrastructures, migrant infrastructures, migration, rural, welcoming spaces, City planning, HT165.5-169.9
Abstract

In recent decades, shrinking areas in rural Spain have sought the arrival of newcomers. This migration is driven mainly by economic reasons and is not related to regionalizing or redistribution migration policies. The main contribution of this article is to highlight how the articulation between social agents’ (public administrations, third sector, enterprises, migrant communities, and civil society) strategies and infrastructuring practices, within the framework of political, social, and economic structural contexts, has crystalized into specific “welcoming spaces,” impacting newcomers’ access to resources. The main innovation lies in the identification of an analysis model applied to three different types of “welcoming spaces” of attraction, arrival, and settlement, considering their impact on other mobilities. We have named them in order to represent the connection of rural territories with nature: the waves, the oak, and the river. The analysis reveals the factors that favor but also block access to resources for newcomers. This has allowed us to design an ideal type of welcoming space, which we have called “Daisy,” and which beyond its theoretical value, could facilitate the revitalization of shrinking areas. “Looking for Daisies” represents the desire of local social actors, lost in the disjointed way in which infrastructuring practices are managed, to reach this goal. Framed under the Horizon 2020-funded program Welcoming Spaces—Investing in “Welcoming Spaces” in Europe: Revitalizing Shrinking Areas by Hosting non-EU Migrants (H2020-SC6-Migration-2019-870952), the research is based on qualitative fieldwork (comprising 75 semi-structured interviews and participant observation), carried out in three localities in two regions of Spain (Galicia and Castilla León).

Published
2024
Full Text
View/download PDF

4. Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial

Author

González-Martín, Antonio, Rubio, María Jesús, Heitz, Florian, Depont Christensen, René, Colombo, Nicoletta, Van Gorp, Toon, Romeo, Margarita, Ray-Coquard, Isabelle, Gaba, Lydia, Leary, Alexandra, De Sande, Luis Miguel, Lebreton, Coriolan, Redondo, Andrés, Fabbro, Michel, Barretina Ginesta, Maria-Pilar, Follana, Philippe, Pérez-Fidalgo, J. Alejandro, Rodrigues, Manuel, Santaballa, Ana, Sabatier, Renaud, Bermejo-Pérez, Maria José, Lotz, Jean-Pierre, Pardo, Beatriz, Marquina, Gloria, Sánchez-Lorenzo, Luisa, Quindós, María, Estévez-García, Purificación, Guerra Alía, Eva, Manso, Luis, Casado, Victoria, Kommoss, Stefan, Tognon, Germana, Henry, Stéphanie, Bruchim, Ilan, Oaknin, Ana, and Selle, Frédéric

Published
2024
Full Text
View/download PDF

5. Phase II clinical trial assessing the efficacy of enzalutamide in advanced non-resectable granulosa cell ovarian tumors: The GREKO III study (GETHI2016–01)

Author

García-Donas, Jesus, Redondo, Andres, Santaballa, Ana, Garrigos, Laia, Rubio, Mª. Jesus, Lainez, Nuria, González, María Iglesias, Cueva, Juan Fernando, Barquin, Arantzazu, Grazioso, Tatiana P., Hurtado, Alicia, Sevillano, Elena, Grande, Enrique, Rodriguez-Moreno, Juan Francisco, and Navarro, Paloma

Published
2024
Full Text
View/download PDF

7. Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study

Author

Kristeleit, Rebecca, Leary, Alexandra, Delord, Jean Pierre, Moreno, Victor, Oaknin, Ana, Castellano, Daniel, Shappiro, Geoffrey I., Fernández, Cristian, Kahatt, Carmen, Alfaro, Vicente, Siguero, Mariano, Rueda, Daniel, Zeaiter, Ali, Awada, Ahmad, Santaballa, Ana, Zaman, Khalil, Sehouli, Jalid, and Subbiah, Vivek

Published
2023
Full Text
View/download PDF

8. Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Álamo IV registry

Author

Martín, Miguel, Carrasco, Eva, Rodríguez-Lescure, Álvaro, Andrés, Raquel, Servitja, Sonia, Antón, Antonio, Ruiz-Borrego, Manuel, Bermejo, Begoña, Guerrero, Ángel, Ramos, Manuel, Santaballa, Ana, Muñoz, Montserrat, Cruz, Josefina, Lopez-Tarruella, Sara, Chacón, Jose I., Álvarez, Isabel, Martínez, Purificación, Miralles, Juan J., Polonio, Óscar, Jara, Carlos, and Aguiar-Bujanda, David

Published
2023
Full Text
View/download PDF

10. Open-label phase II clinical trial of ketoconazole as CYP17 inhibitor in metastatic or advanced non-resectable granulosa cell ovarian tumors: the GREKO (GRanulosa Et KetOconazole) trial, GETHI 2011-03

Author

Garcia-Donas, Jesus, Hurtado, Alicia, Garrigos, Laia, Santaballa, Ana, Redondo, Andres, Vidal, Laura, Lainez, Nuria, Guerra, Eva, Rodriguez, Victor, Cueva, Juan, Bover, Isabel, Palacio, Isabel, Rubio, Maria Jesus, Prieto, Mario, Lopez-Guerrero, Jose Antonio, Rodriguez-Moreno, Juan Francisco, Garcia-Casado, Zaida, Garcia-Martinez, Elena, Taus, Alvaro, de Castro, Ignacio Pérez, Navarro, Paloma, and Grande, Enrique

Published
2023
Full Text
View/download PDF

11. A Smart Digital Health Platform to Enable Monitoring of Quality of Life and Frailty in Older Patients with Cancer: A Mixed-Methods, Feasibility Study Protocol

Author

Papachristou, Nikolaos, Kartsidis, Panagiotis, Anagnostopoulou, Alexandra, Marshall-McKenna, Rebecca, Kotronoulas, Grigorios, Collantes, Gonzalo, Valdivieso, Bernardo, Santaballa, Ana, Conde-Moreno, Antonio José, Domenech, Juan Ramón, Kokoroskos, Emmanouil, Papachristou, Panagiotis, Sountoulides, Petros, Levva, Sophia, Avgitidou, Kelly, Tychala, Christiana, Bakogiannis, Costas, Stafylas, Panos, Ramon, Zoe Valero, Serrano, Andreia, Tavares, Vânia, Fernandez-Luque, Luis, Hors-Fraile, Santiago, Billis, Antonios, and Bamidis, Panagiotis D.

Published
2023
Full Text
View/download PDF

13. Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme

Author

Cueva, Juan F., Palacio, Isabel, Churruca, Cristina, Herrero, Ana, Pardo, Beatriz, Constenla, Manuel, Santaballa, Ana, Manso, Luis, Estévez, Purificación, Maximiano, Constanza, Legerén, Marta, Marquina, Gloria, de Juan, Ana, Quindós, María, Sánchez, Luisa, Barquin, Arantzazu, Fernández, Isaura, Martín, Cristina, Juárez, Asunción, Martín, Teresa, García, Yolanda, Yubero, Alfonso, Gallego, Alejandro, Martínez Bueno, Alejandro, Guerra, Eva, and González-Martín, Antonio

Published
2023
Full Text
View/download PDF

14. Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain – A GEICO study

Author

Alfonso Yubero, Aranzazu Barquín, Purificación Estévez, Bella Pajares, Luisa Sánchez, Piedad Reche, Jesús Alarcón, Julia Calzas, Lydia Gaba, José Fuentes, Ana Santaballa, Carmen Salvador, Luis Manso, Ana Herrero, Álvaro Taus, Raúl Márquez, Julia Madani, María Merino, Gloria Marquina, Victoria Casado, Manuel Constenla, María Gutiérrez, Alba Dosil, and Antonio González-Martín

Subjects
Rucaparib, Recurrent ovarian cancer, Maintenance, Treatment, PARP inhibitor, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background: Rucaparib is a poly(ADP-ribose) polymerase inhibitor approved in Europe as maintenance therapy for recurrent platinum-sensitive (Pt-S) ovarian cancer (OC). The Rucaparib Access Programme (RAP) was designed to provide early access to rucaparib for the above-mentioned indication, as well as for patients with BRCA-mutated Pt-S or platinum-resistant (Pt-R) OC and no therapeutic alternatives. Methods: In this observational, retrospective study we analysed the efficacy and safety of rucaparib within the RAP in Spain. Hospitals associated with the Spanish Ovarian Cancer Research Group (GEICO) recruited patients with high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer treated with rucaparib 600 mg twice daily as maintenance or treatment (Pt-S/Pt-R) in the RAP. Baseline characteristics, efficacy, and safety data were collected. Results: Between July 2020 and February 2021, 51 patients treated in 22 hospitals in the RAP were included in the study. Eighteen patients with a median of 3 (range, 1–6) prior treatment lines received rucaparib as maintenance; median progression-free survival (PFS) for this group was 9.1 months (95% confidence interval [CI], 4.2–11.6 months). Among 33 patients (median 5 [range, 1–9] prior treatment lines) who received rucaparib as treatment, 7 and 26 patients had Pt-S and Pt-R disease, respectively. Median PFS was 10.6 months (95% CI, 2.5 months-not reached) in the Pt-S group and 2.2 months (95% CI, 1.1–3.2 months) in the Pt-R group. Grade ≥ 3 treatment-emergent adverse events were reported in 39% of all patients, the most common being anaemia (12% and 15% in the maintenance and treatment groups, respectively). At data cut-off, 5 patients remained on treatment. Conclusion Efficacy results in these heavily pre-treated patients were similar to those from previous trials. The safety profile of rucaparib in real life was predictable and manageable.

Published
2022
Full Text
View/download PDF

15. Rucaparib for PARP inhibitor-pretreated ovarian cancer: A GEICO retrospective subgroup analysis from the Spanish Rucaparib Access Program

Author

Alfonso Yubero, Purificación Estévez, Aránzazu Barquín, Luisa Sánchez, Ana Santaballa, Bella Pajares, Piedad Reche, Carmen Salvador, Luis Manso, Raúl Márquez, and Antonio González-Martín

Subjects
Ovarian cancer, PARP inhibitor, Rechallenge, Real-world data, Rucaparib, Gynecology and obstetrics, RG1-991, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

The poly(ADP-ribose) polymerase inhibitor (PARPi) rucaparib is approved as maintenance therapy for patients with platinum-sensitive recurrent high-grade ovarian cancer (HGOC). The efficacy and safety of rucaparib after PARPi therapy are largely unknown; therefore, we analyzed outcomes in the subgroup of PARPi-pretreated patients from Spanish hospitals participating in the Rucaparib Access Program. This post hoc subgroup analysis explored baseline characteristics, treatment exposure, safety, effectiveness, and subsequent therapy among women receiving rucaparib 600 mg twice daily after at least one prior PARPi for HGOC. Of 14 women eligible for the analysis, 11 (79%) had tumors harboring BRCA1/2 mutations. Patients had received a median of 5 (range 3–8) treatment lines before rucaparib. Twelve patients (86%) had previously received olaparib and two (14%) niraparib; 12 patients received rucaparib as treatment for platinum-resistant HGOC, one as treatment for platinum-sensitive HGOC, and one as maintenance therapy. Progression-free survival was 0.2–9.1 months. One of seven patients assessable for response by RECIST achieved stable disease. Adverse events occurred in 11 patients (79%; grade 3 in 29%), leading to treatment interruption in eight patients (57%), dose reduction in six (43%), but treatment discontinuation in only one (7%). No new safety signals were observed. This is one of the first reported series of real-world data on rucaparib after prior PARPi for HGOC. In this heavily pretreated population, rucaparib demonstrated meaningful activity in some patients and tolerability consistent with previous prospective trials. Future investigation should focus on identifying patients who may benefit from rucaparib after prior PARPi exposure.

Published
2023
Full Text
View/download PDF

16. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Author

Sevelda, Paul, Haslbauer, Ferdinand, Penzinger, Monika, Öhler, Leopold, Tinchon, Christoph, Greil, Richard, Heibl, Sonja, Bartsch, Rupert, Wette, Viktor, Singer, Christian F., Pasterk, Claudia, Helfgott, Ruth, Pristauz-Telsnigg, Gunda, Stöger, Herbert, Weltermann, Angsar, Egle, Daniel, Thiel, Irene, Fuchs, David, Rumpold, Holger, Strasser-Weippl, Kathrin, Rautenberg, Beate, Müller, Volkmar, Schmidt, Marcus, Paepke, Stefan, Aydogdu, Mustafa, Thomssen, Christoph, Rom, Joachim, Mau, Christine, Fasching, Peter, Göhring, Uwe-Jochen, Kühn, Thorsten, Noeding, Stefanie, Kümmel, Sherko, Hackmann, John, Stickeler, Elmar, Joshi, Abhishek, Dewar, Joanna, Friedlander, Michael, Phillips, Kelly-Anne, Antill, Yoland, Woodward, Natasha, Abdi, Ehtesham, Tiley, Susan, George, Mathew, Boadle, David, Goodwin, Annabel, van der Westhuizen, Andre, Kannourakis, George, Murray, Nicholas, McCarthy, Nicole, Kroep, Judith, de Boer, Maaike, Heijns, Joan, Jager, Agnes, Erdkamp, Franciscus, Bakker, Sandra, Sonke, Gabe S., Sami, Amer, Mackey, John, Prady, Catherine, Eisen, Andrea, Desbiens, Christine, Patocskai, Erica, Ferrario, Cristiano, Gelmon, Karen, Bordeleau, Louise, Chalchal, Haji, Niraula, Saroj, ido wolf, Senkus, Elżbieta, Duhoux, François, Randal d’Hondt, Luce, Sylvie, Roodenbeke, Daphné t’Kint de, Papadimitriou, Konstantinos, Borms, Marleen, Quaghebeur, Claire, Jacot, William, Brain, Etienne, Venat-Bouvet, Laurence, Lortholary, Alain, Nowecki, Zbigniew, Cardoso, Fátima, Hayward, Richard, Bella, Santiago, Lazzaro, Mauricio Fernández, Pilnik, Norma, Fein, Luis E., Blajman, Cesar, Lerzo, Guillermo, Varela, Mirta, Zarba, Juan Jose, Kaen, Diego, Constanzo, Maria Victoria, Tio, Joke, Siggelkow, Wulf, Jackisch, Christian, Grischke, Eva Maria, Zahm, Dirk, Tato-Varela, Sara, Schmatloch, Sabine, Klare, Peter, Stefek, Andrea, Rhiem, Kerstin, Hoffmann, Oliver, Deryal, Mustafa, Gröll, Isolde, Ledwon, Peter, Uleer, Christoph, Krabisch, Petra, Potenberg, Jochem, Darsow, Maren, Park-Simon, Tjoung-Won, Höffkes, Heinz-Gert, Emde, Till-Oliver, Graffunder, Gerd, Tomé, Oliver, Forstmeyer, Dirk, Terhaag, Jürgen, Salat, Christoph, Kast, Karin, Weniger, Steffi, Schreiber, Carsten, Heinrich, Bernhard, Dieterich, Max, Wüllner, Michaela Penelope, Conejero, Raquel Andrés, García Sáenz, José Ángel, Martinez, Lourdes Calvo, Lanza, Angels Arcusa, Murillo, Serafín Morales, Carrasco, Fernando Henao, Tormo, Salvador Blanch, López, Isabel Álvarez, Delgado Mingorance, Juan Ignacio, Gomez, Elena Álvarez, Santisteban, Marta, Jurado, Josefina Cruz, Quiroga, Vanesa, Borrego, Manuel Ruiz, Martínez de Dueñas, Eduardo, Alés Martínez, Jose Enrique, De la Haba, Juan, Jañez, Noelia Martínez, Lescure, Álvaro Rodríguez, Torres, Antonio Antón, Crusades, Gema Llort, González-Santiago, Santiago, Aragones, Antonia Marquez, Ortega, Ana Laura, Molins, Agusti Barnadas, Chacón López-Muñiz, José Ignacio, Jiménez, Miguel Martín, Bertrán, Ana Santaballa, Rodríguez, César, Cortijo, Lucía González, Cretella, Elisabetta, Cortesi, Laura, Ruggeri, Enzo Maria, Verusio, Claudio, Gori, Stefania, Bonetti, Andrea, Mosconi, Anna Maria, Johannsson, Oskar, Jerusalem, Guy, Neven, Patrick, Nagy, Tünde, Pinotti, Graziella, Colleoni, Marco A., Bernardo, Antonio, Gianni, Lorenzo, Bucci, Eraldo, Biganzoli, Laura, Dedes, Konstantin, Novak, Urban, Zaman, Khalil, Braybrooke, Jeremy, Winter, Matthew, Rea, Daniel, Kelleher, Muireann, Barrett, Sophie, Chan, Stephen, Hickish, Tamas, Hurwitz, Jane, Conibear, John, Jegannathen, Apurna, Parton, Marina, Tutt, Andrew, Allerton, Rozenn, Borley, Annabel, Armstrong, Anne, Copson, Ellen, Levitt, Nicola, Abraham, Jean, Perren, Timothy, Roylance, Rebecca, Ishida, Kazushige, Toyama, Tatsuya, Masuda, Norikazu, Watanabe, Junichiro, Tokunaga, Eriko, Kinoshita, Takayuki, Rai, Yoshiaki, Takada, Masahiro, Yanagita, Yasuhiro, Nakamura, Rikiya, Nakayama, Takahiro, Naoi, Yasuto, Iwata, Hiroji, Nakamura, Seigo, Takahashi, Masato, Aogi, Kenjiro, Tsugawa, Koichiro, Mukai, Hirofumi, Takano, Toshimi, Osaki, Akihiko, Sato, Nobuaki, Yamauchi, Hideko, Tokuda, Yutaka, Ito, Mitsuya, Sugimoto, Takeki, Bahadur, Shakeela W., Ganz, Patricia A., Lu, Min J., Mita, Monica M., Waisman, James, Polikoff, Jonathan A., Telli, Melinda L., Seaward, Samantha A., Suga, J. Marie, Durna, Lara N., Carney, Jennifer Fu, Menter, Alex, Puthillath, Ajithkumar, Rohatgi, Nitin, Feusner, James H., Bobolis, Kristie A., Eisenberg, Peter D., Wong, Derrick, Borges, Virginia F., Urquhart, Alexander T., Hofstatter, Erin W., McCarron, Edward C., Isaacs, Claudine, Herbolsheimer, Pia, Varadarajan, Ramya, Raben, Adam, Deveras, Ruby Anne E., Valdes-Albini, Frances, Mahtani, Reshma L., Meisel, Jane L., Sumrall, Bradley T., Jones, Cheryl F., Ofori, Samuel N., Sumida, Kenneth N.M., Karwal, Mark, Wilbur, Deborah W., Singh, (Joe), Spector, David M., Schallenkamp, John, Merkel, Douglas E., Lo, Shelly S., Khosla, Pam G., Cristofanilli, Massimo, Flaum, Lisa, Hoskins, Kent F., Cobleigh, Melody A., Lambiase, Elyse A., Hahn, Olwen M., Oliff, Ira A., Faller, Bryan A., Wade, James L., Burhani, Nafisa D., Gil, Amaryllis, Einhorn, Harvey E., Storniolo, Anna M.V., Chang, Brian K., Kalra, Maitri, Robin, Erwin L., Ansari, Bilal, Sharma, Priyanka, Dakhil, Shaker R., Deming, Richard L., Cole, John T., Hanson, David S., Ochoa, Augusto C., Garber, Judy E., Zimbler, Harvey, Armstrong, Deborah K., Tkaczuk, Katherine H.R., Riseberg, David A., O'Connor, Brian M., Openshaw, Thomas H., Zakalik, Dana, Vakhariya, Cynthia M., Schott, Anne F., Simon, Michael S., Doyle, Thomas J., Al Baghdadi, Tareq, VanderWoude, Amy, Flynn, Patrick J., Zera, Richard T., Friday, Bret E.B., Ruddy, Kathryn J., Smith, Ron, Ademuyiwa, Olabisi, Foluso, Ellis, Robert, Carlson, Jay W., Marchello, T, Benjamin, Levine, Edward A., Marcom, Paul K., Harkness, Cameron B., Tan, Antoinette R., Charles, William J., Kuzma, Charles S., Asaad, Shonda, Radford, James E., Steen, Preston D., Unnikrishnan, Madhu, Seeger, Grant R., Leu, Kirsten M.H., Copur, Mehmet S., Hauke, Ralph J., Soori, Gamini S., Arrick, Bradley A., Reeder, Jennifer G., Toppmeyer, Deborah L., Dayao, Zoneddy R., Adams, Sylvia, Andreopoulou, Eleni, Allison, Magnuson, Anampa Mesias, Jesus D., Sharma, Ruby, Ramaswamy, Bhuvaneswari, Gerds, Aaron T., Shenk, Robert R., Gross, Howard M., Trehan, Shruti, Razaq, Wajeeha, Mansoor, Abdul H., Hilton, Christie J., Brufsky, Adam M., Huynh, Chanh, Chowdhury, Nabila, Domchek, Susan M., Sigurdson, Elin R., Cescon, Terrence P., Rovito, Marc A., DeNittis, Albert S., Vogel, Victor G., Julian, Thomas B., Boyle, L.E., Baez-Diaz, Luis, Brescia, Frank J., Doster, John E., Siegel, Robert D., Wong, Lucas, Patel, Tejal, Nangia, Julie R., Jones, Catherine A., Cannon, George M., Bear, Harry D., Vachhani, Hetal, Wilkinson, Mary, Wood, Marie E., Yan, Fengting, Sui, Xingwei, van Haelst, Carol M., Specht, Jennifer M., Zhuo, Ying, Qamar, Rubina, Ryan, Matthew L., Stockham, Abigail, Virani, Shamsuddin, Gayle, Arlene A., Jubelirer, Steven J., Kurian, Sobha, Salkeni, Mohamad A., Loman, Niklas, Linderholm, Barbro, Silander, Gustav, Hallbeck, Anna-Lotta, von Wachenfeldt Väppling, Anna, Curtit, Elsa, Cardoso, Catarina, Braga, Sofia, Abreu, Miguel, Casa-Nova, Mafalda, Nave, Mónica, Ciruelos Gil, Eva María, Gelpi, Judith Balmaña, Ortega, Adela Fernández, Padró, Josep Gumà, Bermejo de las Heras, Begoña, Cao, María González, Bañuelos, Juan Cueva, Company, Jesús Alarcon, Villaró, Gemma Viñas, Estevez, Laura García, Huober, Jens, Busch, Steffi, Fehm, Tanja, Hahn, Antje, Grafe, Andrea, Noesselt, Thomas, Dewitz, Thomas, Wagner, Harald, Bechtner, Christina, Weigel, Michael, Kolberg, Hans-Christian, Decker, Thomas, Thomalla, Jörg, Hesse, Tobias, Harbeck, Nadia, Jens-Uwe Blohmer, Jan Schröder, Wolf Sütterlin, Marc, Altena, Renske, Chiu, Chang-Fang, Chen, Shin-Cheh, Hou, Ming-Feng, Chang, Yuan-Ching, Chen, Shang-Hung, Chen, Shou-Tung, Huang, Chiun-Sheng, Yeh, Dah-Cherng, Yu, Jyh-Cherng, Tseng, Ling-Ming, Chung, Wei-Pang, Mailliez, Audrey, Petit, Thierry, Delaloge, Suzette, Lévy, Christelle, Dalivoust, Philippe, Extra, Jean-Marc, Mouret-Reynier, Marie-Ange, Hardy-Bessard, Anne-Claire, Simon, Hélène, L'Haridon, Tiffenn, Mege, Alice, Giacchetti, Sylvie, Chakiba-Brugere, Camille, Gratet, Alain, Pottier, Virginie, Ferrero, Jean-Marc, Tennevet, Isabelle, Perrin, Christophe, Canon, Jean-Luc, Joris, Sofie, Shao, Zhimin, Xu, Binghe, Jiang, ZeFei, Sun, Qiang, Shen, Kunwei, Pang, Da, Zhang, Jin, Wang, Shui, Yang, Hongjian, Liao, Ning, Zheng, Hong, Fu, Peifen, Song, Chuangui, Wang, Yongsheng, Fan, Zhimin, Geng, Cuizhi, Tredan, Olivier, Landherr, László, Kaufman, Bella, Yerushalmi, Rinat, Uziely, Beatrice, Conte, Pierfranco, Zamagni, Claudio, Bianchini, Giampaolo, De Laurentiis, Michelino, Tondini, Carlo, Gebbia, Vittorio, Ciccarese, Mariangela, Sarosiek, Tomasz, Mackiewicz, Jacek, Słowińska, Anna, Kalinka, Ewa, Huzarski, Tomasz, Im, Seock-Ah, Jung, Kyung Hae, Sohn, Joo Hyuk, Kim, Jee Hyun, Lee, Keun Seok, Park, Yeon Hee, Lee, Kyoung Eun, Chae, Yee Soo, Cho, Eun Kyung, Geyer, C.E., Jr., Garber, J.E., Gelber, R.D., Yothers, G., Taboada, M., Ross, L., Rastogi, P., Cui, K., Arahmani, A., Aktan, G., Armstrong, A.C., Arnedos, M., Balmaña, J., Bergh, J., Bliss, J., Delaloge, S., Domchek, S.M., Eisen, A., Elsafy, F., Fein, L.E., Fielding, A., Ford, J.M., Friedman, S., Gelmon, K.A., Gianni, L., Gnant, M., Hollingsworth, S.J., Im, S.-A., Jager, A., Jóhannsson, Ó. Þ, Lakhani, S.R., Janni, W., Linderholm, B., Liu, T.-W., Loman, N., Korde, L., Loibl, S., Lucas, P.C., Marmé, F., Martinez de Dueñas, E., McConnell, R., Phillips, K.-A., Piccart, M., Rossi, G., Schmutzler, R., Senkus, E., Shao, Z., Sharma, P., Singer, C.F., Španić, T., Stickeler, E., Toi, M., Traina, T.A., Viale, G., Zoppoli, G., Park, Y.H., Yerushalmi, R., Yang, H., Pang, D., Jung, K.H., Mailliez, A., Fan, Z., Tennevet, I., Zhang, J., Nagy, T., Sonke, G.S., Sun, Q., Parton, M., Colleoni, M.A., Schmidt, M., Brufsky, A.M., Razaq, W., Kaufman, B., Cameron, D., Campbell, C., and Tutt, A.N.J.

Published
2022
Full Text
View/download PDF

22. Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain – A GEICO study

Author

Yubero, Alfonso, Barquín, Aranzazu, Estévez, Purificación, Pajares, Bella, Sánchez, Luisa, Reche, Piedad, Alarcón, Jesús, Calzas, Julia, Gaba, Lydia, Fuentes, José, Santaballa, Ana, Salvador, Carmen, Manso, Luis, Herrero, Ana, Taus, Álvaro, Márquez, Raúl, Madani, Julia, Merino, María, Marquina, Gloria, Casado, Victoria, Constenla, Manuel, Gutiérrez, María, Dosil, Alba, and González-Martín, Antonio

Published
2022
Full Text
View/download PDF

23. Plasma mutational burden in PIK3CA and TP53 independently predicts early progression in patients with HR+/HER2- metastatic breast cancer (MBC) enrolled in the GEICAM/2014-12 FLIPPER trial.

Author

Rojo Todo, Federico Gustavo, primary, Meier, Lara, additional, Martínez, Maria Teresa, additional, Esteban López, María, additional, Paris, Lorena, additional, O'Connor, Miriam, additional, De la Cruz Merino, Luis, additional, Santaballa, Ana, additional, Martinez-Jañez, Noelia, additional, Moreno Antón, Fernando, additional, Fernández, Isaura, additional, Alarcón Company, Jesús, additional, Keane, Maccon, additional, Garcia-Palomo, Andrés, additional, Starus, Anna, additional, Portela, Marta, additional, Herranz, Jesús, additional, Caballero, Rosalia, additional, Jones, Frederick, additional, and Albanell, Joan, additional

Published
2024
Full Text
View/download PDF

24. Use of liquid biomarker thymidine kinase activity (TKa) to predict outcome and progression in patients with metastatic breast cancer (MBC) in the GEICAM/2014-12 FLIPPER trial.

Author

Albanell, Joan, primary, Williams, Amy, additional, Martínez, Maria Teresa, additional, Ritzen, Hanna, additional, Paris, Lorena, additional, O'Connor, Miriam, additional, De la Cruz Merino, Luis, additional, Santaballa, Ana, additional, Martinez-Jañez, Noelia, additional, Moreno Antón, Fernando, additional, Fernández, Isaura, additional, Alarcón Company, Jesús, additional, Guerra, Juan Antonio, additional, Ruiz-Borrego, Manuel, additional, Morris, Patrick G., additional, Portela, Marta, additional, Herranz, Jesús, additional, Caballero, Rosalia, additional, Bergqvist, Mattias, additional, and Rojo Todo, Federico Gustavo, additional

Published
2024
Full Text
View/download PDF

25. Role of the receptor for advanced glycation end products (RAGE) in blood as a potential biomarker for progression to olaparib: A post hoc analysis of patients with platinum-resistant ovarian cancer (PROC) treated in the ROLANDO-GEICO 1601 trial.

Author

Perez-Fidalgo, Jose Alejandro, primary, Tavira, Beatriz, additional, Peña, Carlos J, additional, Guerra, Eva, additional, Martínez-Pretel, Juan José, additional, García, Yolanda, additional, Pineda, Begoña, additional, Iglesias, María, additional, Hernández-Sosa, María, additional, Estévez-García, Purificación, additional, Santaballa, Ana, additional, Manso Sánchez, Luis, additional, and González-Martín, Antonio, additional

Published
2024
Full Text
View/download PDF

26. Quality of life with palbociclib plus fulvestrant placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial

Author

Ariadna Tibau, M. Teresa Martínez, Manuel Ramos, Luis De La Cruz-Merino, Ana Santaballa, Miriam O’Connor, Noelia Martínez-Jañez, Fernando Moreno, Isaura Fernández, Juan Antonio Virizuela, Jesús Alarcón, Juan de La Haba-Rodríguez, Pedro Sánchez-Rovira, Cinta Rosa Albacar, Coralia Bueno Muiño, Catherine Kelly, Maribel Casas, Susana Bezares, Libertad Rosell, and Joan Albanell

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Background: In the FLIPPER trial, palbociclib/fulvestrant significantly improved progression-free survival (PFS) compared with placebo/fulvestrant in postmenopausal women with HR+/HER2− advanced breast cancer (ABC). Objective: We assessed health-related quality of life (QoL) using patient-reported outcomes (PROs). Design and methods: In this phase II double-blinded study, PROs were assessed at baseline after every three cycles and at the end of the treatment using the European Organisation for Research and Treatment of Cancer QLQ-C30 and QLQ-BR23. Time to deterioration (TTD) in global health status (GHS)/QoL was defined as a decrease of ⩾10 points. Changes from baseline (CFB) and TTD were analysed using linear mixed-effect and Cox regression models, respectively. Results: Of the 189 randomised (1:1) patients, 178 (94%) completed ⩾1 post-baseline assessment; 50% received ⩾22 cycles of study treatment, with a questionnaire compliance >90%. Mean baseline scores were comparable between arms. GHS/QoL scores were maintained throughout the palbociclib/fulvestrant treatment. CFB showed significant differences for GHS/QoL, appetite loss, constipation and systemic therapy side effect scores favouring placebo/fulvestrant. TTD in GHS/QoL was delayed in placebo/fulvestrant versus palbociclib/fulvestrant [30.3 versus 11.1 months; adjusted hazard ratio (aHR): 1.57, 95% CI: 1.03–2.39, p = 0.036]; this difference was not significant in patients with progressive disease (aHR: 1.2, 95% CI: 0.6–2.2, p = 0.658). No statistically significant differences in TTD were found for the other QLQ-C30 and QLQ-BR23 scales. Conclusions: Although TTD in GHS/QoL was prolonged with placebo/fulvestrant, no differences were observed on other functional or symptom scales. This finding and the improvement in PFS support the combination of palbociclib/fulvestrant as a beneficial therapeutic option for HR+/HER2− ABC. Trial registration number: Sponsor Study Code: GEICAM/2014-12 EudraCT Number: 2015-002437-21 ClinTrials.gov reference: NCT02690480

Published
2023
Full Text
View/download PDF

31. Sunlight-Driven Photodegradation of RB49 Dye Using TiO 2 -P25 and TiO 2 -UV100: Performance Comparison.

Author

Zaaboul, Fatima, Canle, Moisés, Haoufazane, Chaimaa, Santaballa, Juan Arturo, Hammouti, Belkheir, Azzaoui, Khalil, Jodeh, Shehdeh, Hadjadj, Aomar, and El Hourch, Abderrahim

Subjects
PHOTOCATALYTIC water purification, PHOTODEGRADATION, REACTIVE dyes, TITANIUM dioxide, SCANNING electron microscopy, PHOTOCATALYSIS
Abstract

By combining measurements of photocatalysis under solar irradiation with measurements of total organic carbon, we have compared the performance of two TiO2-based photocatalysts in the photodegradation of the dye Reactive Blue 49 (RB49). TiO2-P25 and TiO2-UV100 commercial photocatalysts were tested within a concentration ranging from 0.5 to 4 g/L. The dye solution concentration was varied from 10 to 50 mg/L and its pH was increased from 3 to 9. Extensive characterization of the photocatalysts was performed using Fourier-transform infrared spectroscopy, scanning electron microscopy and X-ray diffraction. TiO2-UV100 proved to be more active in adsorbing RB49 dye than TiO2-P25. At low dye concentrations, the adsorption equilibrium is reached in 15 min. This time increases to 1 h at higher concentrations. The photocatalytic degradation of aqueous RB49 under sunlight was monitored by UV-Vis spectrophotometry. The apparent rate constant of dye photodegradation with TiO2-UV100 is twice that of TiO2-P25. The total organic carbon (TOC) analysis showed a removal of around 98% with TiO2-UV100 and only 85% with TiO2-P25 after 3 h of solar irradiation. Over five photocatalytic cycles of 3 h, TiO2-UV100 maintained a more stable and higher efficient photocatalytic performance. All our results converge toward a better photocatalytic performance of TiO2-UV100 for the photodegradation of RB49 dye and indicate that the most decisive factor is its greater capacity to adsorb the pollutant. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

32. A Simple Risk Assesment Method for Continental Waters, Based on Screening Contaminants of Emerging Concern.

Author

Voznakova, Alena, Marín, Zenydia, Santaballa, Juan Arturo, and Canle, Moisés

Subjects
EMERGING contaminants, DRINKING water, ENVIRONMENTAL remediation, ENVIRONMENTAL policy, WATER sampling, CAFFEINE, DICLOFENAC
Abstract

With the aim to build a simple alert system that may be of extended use, a screening for contaminants of emerging concern (CECs) is carried out in the Mero‐Barcés hydrographic watershed, in Cecebre, A Coruña, NW Spain, which feeds the reservoir that supplies drinking water to ≈400 000 inhabitants in the area. Water samples are collected for five years (2015–2019) at six different sampling points, to assess the presence and potential risk of CECs, including some widely used drugs: clofibric acid, paracetamol carbamazepine, diclofenac, ibuprofen, ofloxacin, ketoprofen, and sotalol; an alkaloid: caffeine; synthetic flavourings: galaxolide and tonalide; and a plasticiser: bisphenol A. The most abundant CECs occurring are ibuprofen (>2µg L−1), diclofenac, caffeine, and galaxolide. Samples of treated drinking water show a certain degree of CECs abatement. The presence of nonpolar substances, banned in the EU nowadays, is confirmed. A snapshot of sediments is sampled in 2018–2019, and PAHs and PCBs are quantified, the former being mainly of pyrogenic origin. Based on known properties of quantifiable substances, a traffic‐light system is developed for risk assessment of the state of continental waters, a strategy that may be useful for decission‐makers to implement environmental remediation policies [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

35. A Simple Risk Assesment Method for Continental Waters, Based on Screening Contaminants of Emerging Concern

Author

Santaballa, J. Arturo, Vozňáková, Alena, Marín, Zenydia, Canle, Moisés, Santaballa, J. Arturo, Vozňáková, Alena, Marín, Zenydia, and Canle, Moisés

Abstract

[Abstract] With the aim to build a simple alert system that may be of extended use, a screening for contaminants of emerging concern (CECs) is carried out in the Mero-Barcés hydrographic watershed, in Cecebre, A Coruña, NW Spain, which feeds the reservoir that supplies drinking water to ≈400 000 inhabitants in the area. Water samples are collected for five years (2015–2019) at six different sampling points, to assess the presence and potential risk of CECs, including some widely used drugs: clofibric acid, paracetamol carbamazepine, diclofenac, ibuprofen, ofloxacin, ketoprofen, and sotalol; an alkaloid: caffeine; synthetic flavourings: galaxolide and tonalide; and a plasticiser: bisphenol A. The most abundant CECs occurring are ibuprofen (>2µg L−1), diclofenac, caffeine, and galaxolide. Samples of treated drinking water show a certain degree of CECs abatement. The presence of nonpolar substances, banned in the EU nowadays, is confirmed. A snapshot of sediments is sampled in 2018–2019, and PAHs and PCBs are quantified, the former being mainly of pyrogenic origin. Based on known properties of quantifiable substances, a traffic-light system is developed for risk assessment of the state of continental waters, a strategy that may be useful for decission-makers to implement environmental remediation policies

Published
2024

38. A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study

Author

Gavilá, J., De La Haba, J., Bermejo, B., Rodríguez-Lescure, Á., Antón, A., Ciruelos, E., Brunet, J., Muñoz-Couselo, E., Santisteban, M., Rodríguez Sánchez, C. A., Santaballa, A., Sánchez Rovira, P., García Sáenz, J. Á., Ruiz-Borrego, M., Guerrero-Zotano, A. L., Huerta, M., Cotes-Sanchís, A., Lao Romera, J., Aguirre, E., Cortés, J., and Llombart-Cussac, A.

Published
2020
Full Text
View/download PDF

40. Common Reactivity and Properties of Heme Peroxidases: A DFT Study of Their Origin

Author

Daniel R. Ramos, Paul G. Furtmüller, Christian Obinger, Ángeles Peña-Gallego, Ignacio Pérez-Juste, and J. Arturo Santaballa

Subjects
peroxidase, density functional calculations, compound I, compound II, ferryl oxygen, reduction potential, Therapeutics. Pharmacology, RM1-950
Abstract

Electronic structure calculations using the density-functional theory (DFT) have been performed to analyse the effect of water molecules and protonation on the heme group of peroxidases in different redox (ferric, ferrous, compounds I and II) and spin states. Shared geometries, spectroscopic properties at the Soret region, and the thermodynamics of peroxidases are discussed. B3LYP and M06-2X density functionals with different basis sets were employed on a common molecular model of the active site (Fe-centred porphine and proximal imidazole). Computed Gibbs free energies indicate that the corresponding aquo complexes are not thermodynamically stable, supporting the five-coordinate Fe(III) centre in native ferric peroxidases, with a water molecule located at a non-bonding distance. Protonation of the ferryl oxygen of compound II is discussed in terms of thermodynamics, Fe–O bond distances, and redox properties. It is demonstrated that this protonation is necessary to account for the experimental data, and computed Gibbs free energies reveal pKa values of compound II about 8.5–9.0. Computation indicates that the general oxidative properties of peroxidase intermediates, as well as their reactivity towards water and protons and Soret bands, are mainly controlled by the iron porphyrin and its proximal histidine ligand.

Published
2023
Full Text
View/download PDF

42. Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial

Author

Vergote, Ignace, Scambia, Giovanni, Park, Sang Yoon, Song, Yong Sang, Makarova, Yulia, Trinidad, Joshua, Ngan, Hextan Yuen Sheung, Bamias, Aristotelis, Aravantinos, Gerasimos, Nam, Joo-Hyun, Gorbunova, Vera, Krikunova, Ludmila, Bae, Duk-Soo, Arija, Jose Angel Arranz, Mirza, Mansoor Raza, Zamagni, Claudio, Papandreou, Christos, Raspagliesi, Francesco, Lisyanskaya, Alla, Benzaquen, Ana Oaknin, Tognon, Germana, Ortega, Eugenia, Herraez, Antonio Casado, Buscema, Joseph, Green, Andrew, Burger, Robert, Sakaeva, Dina, Sanchez, Andres Redondo, Ghamande, Sharad, King, Laurel, Petru, Edgar, Peen, Ulla, Takeuchi, Satoshi, Ushijima, Kimio, Martin, Antonio Gonzalez, Kamelle, Scott, Carney, Michael, Marth, Christian, Forget, Frédéric, Bentley, James, Sehouli, Jalid, Colombo, Nicoletta, Zola, Paolo, Kato, Hidenori, Fadeeva, Natalya, Gotovkin, Evgeny, Vladimirov, Vladimir, Marin, Margarita Romeo, Alia, Eva Guerra, Shahin, Mark, Bhoola, Snehalkumar, Tewari, Krishnansu, Anderson, Daniel, Honhon, Brigitte, Pelgrims, Joseph (Gino), Oza, Amit, Jimenez, Jesus Garcia-Donas, Hansen, Vincent, O'Malley, David, Benjamin, Ivor, Renard, Vincent, Van den Bulck, Heidi, Meier, Werner, Haenle, Claudia, Koumakis, Georgios, Yokota, Harushige, Popov, Vadim, Bradley, William, Wenham, Robert, Reid, Robert, McNamara, Donna, Friedman, Richard, Barlin, Joyce, Spirtos, Nicola, Chapman, Julia, Sevelda, Paul, Huizing, Manon, Lamot, Caroline, Goffin, Frédéric, Hondt, Lionel D, Covens, Allan, Spadafora, Silvana, Rautenberg, Beate, Reimer, Toralf, Möbus, Volker, Hilpert, Felix, Gropp-Meier, Martina, Savarese, Antonella, Pignata, Sandro, Verderame, Francesco, Mizuno, Mika, Takano, Hirokuni, Ottevanger, Petronella, Velasco, Andres Poveda, Palacio-Vazquez, Isabel, Law, Amy, McIntyre, Kristi, Teneriello, Michael, Fields, Abbie, Lentz, Samuel, Street, Daron, Schwartz, Benjamin, Mannel, Robert, Lim, Peter, Pulaski, Heather, Janni, Wolfgang, Zorr, Andreas, Karck, Ulrich, Cheng, Ashley Chi Kin, Sorio, Roberto, Gridelli, Cesare, Aoki, Daisuke, Oishi, Tetsuro, Hirashima, Yasuyuki, Boere, Ingrid, Ferrer, Esther Falco, Braly, Patricia, Wilks, Sharon, Lee, Christine, Schilder, Jeanne, Veljovich, Dan, Secord, Angeles, Davis, Kevin, Rojas-Espaillat, Luis, Lele, Shashikant, DePasquale, Stephen, Squatrito, Robert, Schauer, Christian, Dirix, Luc, Vuylsteke, Peter, Joosens, Eric, Provencher, Diane, Lueck, Hans-Joachim, Hein, Alexander, Burges, Alexander, Canzler, Ulrich, Park-Simon, Tjoung-Won, Griesinger, Frank, Gadducci, Angiolo, Alabiso, Oscar, Okamoto, Aikou, Sawasaki, Takashi, Saito, Toshiaki, Ibañez, Ana Herrero, Calomeni, Coralia, Spillman, Monique, Choksi, Janak, Taylor, Nicholas, Muller, Carolyn, Moore, David, DiSilvestro, Paul, Cunningham, Mary, Rose, Peter, Oppelt, Peter, Verhoeven, Didier, Graas, Marie-Pascale, Ghatage, Prafull, Tonkin, Katia, Kurzeder, Christian, Schnappauf, Benjamin, Müller, Volkmar, Schmalzrie, Hannah, Kalofonos, Haralambos, Bruzzone, Milena, Kroep, Judith, Diaz, Cristina Caballero, Garcia, Jeronimo Martinez, Polo, Susana Hernando, Garrison, Mitchell, Rocconi, Rodney, Andrews, Stephen, Bristow, Robert, McHale, Michael, Basil, Jack, Houck III, William, Bell, Maria, Cosin, Jonathan, Modesitt, Susan, Kendrick, James, Wade III, James, Wong, Cheung, Evans, Anthony, Buekers, Thomas, Vanderkwaak, Timothy, Ferriss, James, Darus, Christopher, DAndre, Stacy, Higgins, Robert, Monk, Bradley, Bakkum-Gamez, Jamie, DeMars, Leslie, Van Le, Linda, Puls, Larry, Trehan, Shruti, LaPolla, James, Michelson, Elizabeth Dickson, Merchant, Joseph, Peterson, Christopher, Reid, Gary, Seago, Donald, Zweizig, Susan, Gajewski, Walter, Panwalkar, Amit, Leikermoser, Rudolf, Bogner, Gerhard, Debruyne, Philip, D'hondt, Randal, Berteloot, Patrick, Kerger, Joseph, Biagi, James, Castonguay, Vincent, Welch, Stephen, Muhic, Aida, Heubner, Martin, Grischke, Eva-Maria, Rack, Brigitte, Fleisch, Markus, Lordick, Florian, Pectasides, Dimitrios, Ho, Wing Ming, Selvaggi, Luigi, Vasquez, Flavia Morales, Villanueva, William Orlando Brito, Alavez, Alejandro Molina, Kessels, Lonneke, Bertran, Ana Santaballa, Fernandez, Cesar Mendiola, Fabregat, Miguel Beltran, Del Prete, Salvatore, Elkas, John, Cecchi, Gary, Kumar, Pallavi, Huh, Warner, Messing, Mark, Karimi, Misagh, Kelley, Ann, Edraki, Babak, Mutch, David, Leiserowitz, Gary, Anderson, Jeanne, Lentz, Scott, Chambers, Setsuko, Morris, Robert, Waggoner, Steven, Gordon, Alan, Method, Michael, Johnson, Peter, Lord, Raymond, Drake, Janet, Sivarajan, Kulumani, Midathada, Madhu, Rice, Kristen, Wadsworth, Troy, Pavelka, James, Edwards, Robert, Miller, David Scott, Ford, Patricia Locantore, Hurteau, Jean, Bender, David, Schimp, Veronica, Creasman, William, Lerner, Rachel, Chamberlain, Donald, Kueck, Angela, McDonald, John, Malad, Salman, Robinson-Bennett, Bernice, Davidson, Susan, Krivak, Thomas, Lestingi, Timothy, Arango, Hector, Berard, Paul, Finkelstein, Karen, Gaur, Rakesh, Krasner, Carolyn, Ueland, Frederick, Talmage, Lance, Yamada, Seiko, Sutton, Gregory, Potkul, Ronald, Prasad-Hayes, Monica, Osborne, Janet, Celano, Paul, Thigpen, James, Sharma, Sudarshan, Schilder, Russell, Tammela, Jonathan, Kemeny, Mary, Brown, Amy, Eisenhauer, Eric, Williams, James, Rowland, Kendrith, Nahum, Kenneth, Burke, James, Dar, Zahid, Fleming, Nicole, Gibb, Randall, Guirguis, Alfred, Herzog, Thomas, John, Veena, Kumar, Santhosh, Kamat, Aparna, Kassar, Mohamad, Leitao, Mario, Levine, Lyuba, Mendez, Luis, Patel, Dhimant, Berry, Emily, Warshal, David, Wolf, Judith, Zarwan, Corrine, Collins, Yvonne, Spitzer, Gary, Miller, Brigitte, Einstein, Mark, O'Malley, David M, Van Calster, Ben, Park, Sang-Yoon, del Campo, Josep M, Wenham, Robert M, Covens, Al, Raza Mirza, Mansoor, Kroep, Judith R, Ma, Haijun, Pickett, Cheryl A, and Monk, Bradley J

Published
2019
Full Text
View/download PDF

45. Mechanical Stability Is Key for Large-Scale Implementation of Photocatalytic Surface-Attached Film Technologies in Water Treatment

Author

D.R. Ramos, M. Iazykov, M.I. Fernandez, J.A. Santaballa, and M. Canle

Subjects
photocatalysis, supported photocatalyst, coating, flow photocatalysis, mechanical stability, heterogeneous photocatalysis, Technology, Chemical technology, TP1-1185
Abstract

Replacement of classical tertiary water treatment by chemical-free sunlight-driven photocatalytic units has been often proposed. Photocatalysts are required to be cost-effective, inert, chemically stable, reusable, and easy to separate and also that they are mechanically stable. The effect of mechanical stress on a photoactive TiO2 layer, and on its effectivity for degradation of phenol as a model pollutant, has been studied during photocatalytic water treatment using NUV–vis light. Sol–gel (SG) and liquid phase deposition (LPD) methods have been used to coat spherical glass beads with the photocatalyst (TiO2). Physicochemical characterization of coated glass beads has been performed by N2 adsorption–desorption isotherms, SEM, EDXS, and AFM. Phenol photocatalyzed degradation was carried out both in stirred batch and flow reactors irradiated with a medium-pressure Hg-vapor lamp (λ > 350 nm). Phenol concentration was determined by HPLC, and its photoproducts were identified using HPLC/MS. In the stirred batch reactor, all LPD-coated glass beads displayed higher catalytic activity than SG-coated ones, which increased with calcination temperature, 700°C being the most efficient temperature. Preliminary etching of the glass beads surface yielded dissimilar results; whereas, phenol photodegradation with SG-coated etched glass beads is twice faster than with unetched SG ones, the rate reduces to one-third using LPD etched instead of unetched LPD glass beads. Phenol photodegradation using LPD is similar both in stirred batch and flow reactors, despite the latter uses a lower catalyst load. LPD-etched catalyst was recovered and reused in the stirred batch reactor; its activity reduced sharply after the first use, and it also lost activity in successive runs, ca. 10% of activity after each “use and recover” cycle. In the flow reactor, activity loss after the first experiment and recycling (ca. 30%) was much larger than in the following runs, where the activity remained rather constant through several cycles. LPD is more adequate than SG for TiO2 immobilization onto glass beads, and their calcination at 700°C leads to relatively strong and reactive photocatalytic films. Still, TiO2-coated glass beads exhibited very low photoactivity compared to TiO2-P25 nanoparticles, though their separation is much easier and almost costless. The durability of the catalytic layer increases when using a flow reactor, with the pollutant solution flowing in a laminar regime through the photocatalyst bed. In this way, the abrasion of the photocatalytic surface is largely reduced and its photoactivity is better maintained.

Published
2021
Full Text
View/download PDF

46. Figure S3 from Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/MINOVA Study)

Author

Tavira, Beatriz, primary, Iscar, Teresa, primary, Manso, Luis, primary, Santaballa, Ana, primary, Gil-Martin, Marta, primary, García García, Yolanda, primary, Romeo, Margarita, primary, Iglesias, Maria, primary, de Juan Ferré, Ana, primary, Barretina-Ginesta, María Pilar, primary, Manzano, Aranzazu, primary, Gaba, Lydia, primary, Rubio, María Jesús, primary, de Andrea, Carlos E., primary, and González-Martín, Antonio, primary

Published
2024
Full Text
View/download PDF

47. Supplementary Methods 1 from Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/MINOVA Study)

Author

Tavira, Beatriz, primary, Iscar, Teresa, primary, Manso, Luis, primary, Santaballa, Ana, primary, Gil-Martin, Marta, primary, García García, Yolanda, primary, Romeo, Margarita, primary, Iglesias, Maria, primary, de Juan Ferré, Ana, primary, Barretina-Ginesta, María Pilar, primary, Manzano, Aranzazu, primary, Gaba, Lydia, primary, Rubio, María Jesús, primary, de Andrea, Carlos E., primary, and González-Martín, Antonio, primary

Published
2024
Full Text
View/download PDF

48. Data from Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/MINOVA Study)

Author

Tavira, Beatriz, primary, Iscar, Teresa, primary, Manso, Luis, primary, Santaballa, Ana, primary, Gil-Martin, Marta, primary, García García, Yolanda, primary, Romeo, Margarita, primary, Iglesias, Maria, primary, de Juan Ferré, Ana, primary, Barretina-Ginesta, María Pilar, primary, Manzano, Aranzazu, primary, Gaba, Lydia, primary, Rubio, María Jesús, primary, de Andrea, Carlos E., primary, and González-Martín, Antonio, primary

Published
2024
Full Text
View/download PDF

49. Table S1 from Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/MINOVA Study)

Author

Tavira, Beatriz, primary, Iscar, Teresa, primary, Manso, Luis, primary, Santaballa, Ana, primary, Gil-Martin, Marta, primary, García García, Yolanda, primary, Romeo, Margarita, primary, Iglesias, Maria, primary, de Juan Ferré, Ana, primary, Barretina-Ginesta, María Pilar, primary, Manzano, Aranzazu, primary, Gaba, Lydia, primary, Rubio, María Jesús, primary, de Andrea, Carlos E., primary, and González-Martín, Antonio, primary

Published
2024
Full Text
View/download PDF

50. Experiences of a supportive digital platform for older cancer survivors: the LifeChamps pilot study

Author

Kartsidis, P., primary, Petridis, G., additional, Sountoulides, P., additional, Baxevanis, G., additional, Collantes, G., additional, Roig, N., additional, Naranjo, J.C., additional, Santaballa, A., additional, Conde-Moreno, A.J., additional, Domenech, J.R., additional, Papachristou, P., additional, Kokoroskos, E., additional, Abtahi, F., additional, Kotronoulas, G., additional, Marshal-Mckenna, R., additional, Bamidis, P.D., additional, and Billis, A., additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results